BORA PHARMACEUTICALS LTD Market Cap ($1.49 Billion)
Market Cap & Net Worth: BORA PHARMACEUTICALS LTD (6472)
BORA PHARMACEUTICALS LTD market cap. BORA PHARMACEUTICALS LTD (TW:6472) has a market capitalization of $1.49 Billion (NT$47.22 Billion) as of November 5, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #7047 globally and #214 in its home market, demonstrating a -6.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BORA PHARMACEUTICALS LTD's stock price NT$371.00 by its total outstanding shares 127287359 (127.29 Million). Also see BORA PHARMACEUTICALS LTD operating cash flow efficiency for how efficiently the company converts equity into cash flow.
BORA PHARMACEUTICALS LTD Market Cap History (2023–2026)
BORA PHARMACEUTICALS LTD market cap history from 2023 to 2026. Data shows change from $2.52 Billion to $1.49 Billion (-15.77% CAGR). Check BORA PHARMACEUTICALS LTD share price for real-time trading data and today's change.
BORA PHARMACEUTICALS LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BORA PHARMACEUTICALS LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BORA PHARMACEUTICALS LTD annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.10x
BORA PHARMACEUTICALS LTD's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.66x
BORA PHARMACEUTICALS LTD's market cap is 0.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $2.52 Billion | $14.20 Billion | $3.03 Billion | 0.18x | 0.83x |
| 2024 | $3.02 Billion | $19.25 Billion | $3.94 Billion | 0.16x | 0.77x |
| 2025 | $1.96 Billion | $19.01 Billion | $2.98 Billion | 0.10x | 0.66x |
Competitor Companies of 6472 by Market Capitalization
Companies near BORA PHARMACEUTICALS LTD in the global market cap rankings as of November 5, 2026. Also see balance sheet size of BORA PHARMACEUTICALS LTD for a full breakdown of the balance sheet.
Key companies related to BORA PHARMACEUTICALS LTD by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of BORA PHARMACEUTICALS LTD (2023–2026)
Market capitalization of BORA PHARMACEUTICALS LTD from 2023 to today. Between 2023 and today, BORA PHARMACEUTICALS LTD's market cap moved from $2.52 Billion to $ 1.49 Billion, with a yearly change of -15.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$1.49 Billion | -23.98% |
| 2025 | NT$1.96 Billion | -35.11% |
| 2024 | NT$3.02 Billion | +19.52% |
| 2023 | NT$2.52 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of BORA PHARMACEUTICALS LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more